PTCT Ptc Therapeutics Inc
Price (delayed)
$49.46
Market cap
$3.9B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$4.73
Enterprise value
$3.51B
PTC is a science-driven, global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to globally
Highlights
The EPS is up by 43% year-on-year and by 20% since the previous quarter
The net income has grown by 42% YoY and by 20% from the previous quarter
Ptc Therapeutics's equity has decreased by 34% YoY and by 4.1% QoQ
Ptc Therapeutics's revenue has decreased by 14% YoY and by 10% from the previous quarter
Key stats
What are the main financial stats of PTCT
Market
Valuations
Earnings
Shares outstanding
78.87M
Market cap
$3.9B
Enterprise value
$3.51B
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
4.71
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.35
Revenue
$806.78M
Gross profit
$749.38M
Operating income
-$307.05M
Net income
-$363.3M
EBIT
-$196.13M
EBITDA
-$112.71M
Free cash flow
$63.87M
Per share
Balance sheet
Liquidity
EPS
-$4.73
EPS diluted
-$4.73
Free cash flow per share
$0.83
Book value per share
-$14.24
Revenue per share
$10.5
TBVPS
$19.57
Total assets
$1.71B
Total liabilities
$2.8B
Debt
$389.3M
Equity
-$1.1B
Working capital
$784.55M
Debt to equity
-0.35
Current ratio
2.35
Quick ratio
2.23
Net debt/EBITDA
3.46
Margins
Efficiency
Dividend
EBITDA margin
-14%
Gross margin
92.9%
Net margin
-45%
Operating margin
-38.1%
Return on assets
-20%
Return on equity
N/A
Return on invested capital
-30.9%
Return on capital employed
-17.4%
Return on sales
-24.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
PTCT stock price
How has the Ptc Therapeutics stock price performed over time
Intraday
-0.98%
1 week
4.37%
1 month
-13.27%
1 year
96.19%
YTD
9.57%
QTD
-2.94%
Financial performance
How have Ptc Therapeutics's revenue and profit performed over time
Revenue
$806.78M
Gross profit
$749.38M
Operating income
-$307.05M
Net income
-$363.3M
Gross margin
92.9%
Net margin
-45%
PTCT's operating margin has dropped by 161% since the previous quarter but it is up by 37% year-on-year
The company's operating income has shrunk by 134% QoQ but it rose by 46% YoY
The net income has grown by 42% YoY and by 20% from the previous quarter
The company's net margin rose by 33% YoY and by 11% QoQ
Growth
What is Ptc Therapeutics's growth rate over time
Valuation
What is Ptc Therapeutics stock price valuation
P/E
N/A
P/B
N/A
P/S
4.71
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
4.35
The EPS is up by 43% year-on-year and by 20% since the previous quarter
Ptc Therapeutics's equity has decreased by 34% YoY and by 4.1% QoQ
The price to sales (P/S) is 54% higher than the last 4 quarters average of 3.1 but 8% lower than the 5-year quarterly average of 5.2
Ptc Therapeutics's revenue has decreased by 14% YoY and by 10% from the previous quarter
Efficiency
How efficient is Ptc Therapeutics business performance
The ROS has soared by 60% year-on-year and by 14% since the previous quarter
The ROIC has soared by 56% YoY and by 20% from the previous quarter
Ptc Therapeutics's ROA has soared by 51% YoY and by 18% from the previous quarter
Dividends
What is PTCT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for PTCT.
Financial health
How did Ptc Therapeutics financials performed over time
The total assets is 39% less than the total liabilities
The quick ratio rose by 30% year-on-year and by 12% since the previous quarter
Ptc Therapeutics's current ratio has increased by 16% YoY and by 12% QoQ
The company's debt is 135% higher than its equity
Ptc Therapeutics's equity has decreased by 34% YoY and by 4.1% QoQ
PTCT's debt to equity is up by 31% year-on-year and by 8% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.